ReviewBritish journal of clinical pharmacology2010
Emerging treatment options for type 2 diabetes.
Review in British journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.Obesity (Silver Spring, Md.) · 2023 · on this mapPooled it
- Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Medicine · 2016 · on this mapPooled it
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.Diabetes care · 2021Trial
- In vitro and in silico antiglycation antihyperglycemic and anti-inflammatory properties of chemically profiled fruit extracts of Solanum obtusifolium Dunal.Scientific reports · 2026Article
- Effects ofPharmaceuticals (Basel, Switzerland) · 2025Article
- The Potential of Mesenchymal Stem Cell-Derived Exosomes to Treat Diabetes Mellitus.Biomimetics (Basel, Switzerland) · 2025Review
- Characterization of phenolic compounds and evaluation of anti-diabetic potential inOpen life sciences · 2024Article
- Influence of glimepiride plus sitagliptin on treatment outcome, blood glucose, and oxidative stress in diabetic patients.American journal of translational research · 2022Article
- A novel inducible acute hyperglycemia mouse model for assessing 6-KTP.Biomedical reports · 2019Article
- Hypoglycemic and pancreatic protective effects of Portulaca oleracea extract in alloxan induced diabetic rats.BMC complementary and alternative medicine · 2017Article
- Basic Fibroblast Growth Factor Inhibits Apoptosis and Promotes Proliferation of Adipose-Derived Mesenchymal Stromal Cells Isolated from Patients with Type 2 Diabetes by Reducing Cellular Oxidative Stress.Oxidative medicine and cellular longevity · 2017Article
- Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats.Biochemistry research international · 2015Article
- Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia.Gut · 2014Article
- GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.Diabetes · 2014Article
- Article
- Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.Diabetes care · 2013Article
- A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.International journal of endocrinology · 2013Article
- Article
- DPP-4 inhibition and islet function.Journal of diabetes investigation · 2012Review
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.Nature reviews. Endocrinology · 2012 · on this mapReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) is rapidly increasing in prevalence and is a major public health problem. It is a progressive disease which commonly requires multiple pharmacotherapy. Current options for treatment may have undesirable side effects (particularly weight gain and hypoglycaemia) and contraindications, and little effect on disease progression. Incretin based therapy is one of several newer therapies to improve glycaemia and is available in two different forms, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. Use of these agents results in a 'glucose-dependant' increase in insulin secretion and glucagon suppression resulting in improved glycaemia with low incidence of hypoglycaemia. DPP-4 inhibitors are oral drugs which are weight neutral, while GLP-1 agonists are injected subcutaneously and help promote weight loss while improving glycaemia. GLP-1 agonists have also been shown to increase beta cell mass in rat models. Bariatric surgery is another option for the obese patient with T2DM, with blood glucose normalizing in over half of the patients following surgery. Other therapies in development for the treatment of T2DM include sodium-glucose transporter 2 (SGLT-2) inhibitors, glucagon receptor antagonists, glucokinase activators and sirtuins. In this article, we will review the various existing and emerging treatment options for T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.